ADOLAN 0.04 %

País: Israel

Idioma: anglès

Font: Ministry of Health

ingredients actius:

METHADONE HYDROCHLORIDE

Disponible des:

TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL

Codi ATC:

N07BC02

formulario farmacéutico:

SOLUTION

Composición:

METHADONE HYDROCHLORIDE 0.4 MG/ML

Vía de administración:

PER OS

tipo de receta:

Required

Fabricat per:

TEVA PHARMACEUTICAL INDUSTRIES LTD, ISRAEL

Grupo terapéutico:

METHADONE

Área terapéutica:

METHADONE

indicaciones terapéuticas:

Relief of moderate to severe pain.

Data d'autorització:

2012-02-28

Fitxa tècnica

ADOLAN 30 1. 2012, RH
"
ע עבקנ הז ןולע טמרופ
"
רשואו קדבנ ונכותו תואירבה דרשמ י
."
רשואמ ןולע
:
ראוני
2012
“This leaflet format has been determined by the Ministry of Health
and the content thereof has been
checked and approved.” Date of approval: January 2012.
ADOLAN 0.04%
SOLUTION
COMPOSITION
_Active Ingredient _
Methadone hydrochloride
0.04% (0.4 mg/ml)
_ _
_Other Ingredients _
Saccharin,
methylparaben,
propylparaben,
edicol
supra
blue
EGS,
water
for
injection.
MECHANISM OF ACTION
Methadone
hydrochloride
is
a
synthetic
narcotic
agent
with
analgesic
and
antitussive properties equal to those of morphine but with lower
sedative and addictive
effects. The onset of action occurs 30-60 minutes after an oral dose,
with peak effect
after 90-120 minutes. The duration of action is 4-6 hours.
Methadone is readily absorbed from the gastrointestinal tract. It is
widely distributed
in the tissues and diffuses across the placenta. It is highly
plasma-bound with a half
life of 15-25 hours.
Methadone is metabolized in the liver mainly by N-demethylation and
cyclization.
The metabolites are excreted in the bile and urine. A variable amount
of the dose
appears
in
the
urine
unchanged.
Some
metabolites
are
active.
With
repeated
administration, half life may be greatly prolonged and duration of
action may increase
to
22-48
hours,
possibly
because
of
accumulation
of
methadone
or
of
active
metabolites. Renal excretion is dependent on urinary pH and is higher
in acidic urine.
INDICATIONS
Relief of moderate to severe pain.
CONTRAINDICATIONS
Known hypersensitivity to methadone or to any other ingredient of the
preparation.
Respiratory depression, obstructive airways disease (especially in the
presence of
cyanosis and excessive bronchial secretions) and during an acute
asthma attack
Patients dependent on non-opioid drugs
Concurrent
administration
with
monoamine
oxidase
inhibitors
(including
moclobemide) or within 2 weeks of discontinuation of them.
Head injury and raised intrac